George M. Rodgers, III
( out of 64 reviews )

George M. Rodgers, III, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

St. George Specialty Clinic at Richens Eye Center

Hemophilia Outreach Clinic
St. George
801-213-8301

Sugar House Health Center

Salt Lake City
801-581-2000

  • George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as a classical hematology expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a principal investigator for clinical trials and the Associate Director of the Utah Center for Bleeding and Clotting Disorders.



    For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Pathology (Sub: Hematology)
    Federal Licensing Examination
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 64 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    SUGAR HOUSE HEALTH CENTER

    I was so appreciative that Dr. Rodgers knew what to do to help me have a better quality life. I will be forever grateful. He is very kind and has superior bedside manner,

    October 10, 2024
    SUGAR HOUSE HEALTH CENTER

    He is so good because he really cares about my health and my questions regarding it He is probably going to retire soon and he will be a tough act to follow. God is happy with him.

    July 19, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Rodgers¿ care and treatment improved my quality of life by 200%!

    June 12, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Roger's has taken excellent care of my blood issues and knows where to test for problems that do not always show up on standard blood tests. He is caring and willing to help other care providers by attending my oral surgeries to insure the procedures went as well as possible. Even though they were not performed in the facility where he sees patients. Intelligent and personable, he is a great physician.

    June 07, 2024
    SUGAR HOUSE HEALTH CENTER

    He and his staff are helping keep me alive!

    June 04, 2024
    SUGAR HOUSE HEALTH CENTER

    Very professional and knowledgeable doctor.

    May 16, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Rodgers is the ultimate professional, always on time and on top of my medical issues.

    May 03, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Rodgers was incredible. He listened and ordered appropriate test. I'm so pleased my care is in his hands. Thank you

    April 07, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Rogers is very thorough and speaks in manner we can understand. We feel like he is the best choice for us in dealing with HHT.

    See More Patient Comments

  • George M. Rodgers, M.D., Ph.D. is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah School of Medicine. He started at the University of Utah in 1988. He is the senior adult hemophilia and thrombosis expert in the state of Utah, and also serves as a classical hematology expert for - and receives referrals and consultations from - a six state region. His clinical practice is conducted at the University of Utah's Sugarhouse Clinic. He is the chairman of the University Hospital Adverse Drug Reaction Subcommittee. He is also a principal investigator for clinical trials and the Associate Director of the Utah Center for Bleeding and Clotting Disorders.



    For questions regarding Dr. Rodgers' practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Pathology (Sub: Hematology)
    Federal Licensing Examination
    National Board of Medical Examiners

    Education history

    Fellowship Hematology/Oncology - University of California San Francisco Fellow
    Internal Medicine - Baylor College of Medicine Resident
    Internship Baylor College of Medicine Intern
    Medicine - Tulane University M.D.
    Doctoral Training Pharmacology - Tulane University Ph.D.
    Biochemistry - Louisiana State University B.S.

    Selected Publications

    Journal Article

    1. Lim MY, Rodgers GM, Branch DW, Simonsen SE (2024). Targeting a higher plasma VWF level at time of delivery in pregnant individuals with von Willebrand disease: Outcomes at a single-institution cohort study. Haemophilia, 30(2), 470-477. (Read full article)
    2. Rodgers GM, Mahajerin A (2023). Antithrombin Therapy: Current State and Future Outlook. Clin Appl Thromb Hemost, 29, 10760296231205279. (Read full article)
    3. Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino MD (2022). Five Challenging Cases of Hereditary Antithrombin Deficiency Characterized by Thrombosis or Complicated Pregnancy. J Blood Med, 13, 611-618. (Read full article)
    4. Rodgers GM, Ward JH, Bray PF (2022). 80 years of Clinical Hematology. Br J Haematol, 198(5), 802. (Read full article)
    5. Auerbach M, Macdougall IC, Rodgers GM, Deloughery T, Richards T (2021). The iron revolution: Keeping abreast of the developments in iron therapy. Am J Hematol, 97(3), 250-252. (Read full article)
    6. Sholzberg M, Khair K, Yaish H, Rodgers G, Cruz MS, Meja CM, ermkov Z, Matino D, Teitel J, Barrie A, Werner S, Prondzinski MVD (2021). Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. TH Open, 5(3), e264-e272. (Read full article)
    7. Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY (2021). Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Res Pract Thromb Haemost, 5(2), 356-365. (Read full article)
    8. Lim MY, Wei G, Presson AP, Bray P, Rodgers GM (2020). High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. Blood Coagul Fibrinolysis, 31(8), 522-529. (Read full article)
    9. Williams LB, Javed A, Sabri A, Morgan DJ, Huff CD, Grigg JR, Heng XT, Khng AJ, Hollink IHIM, Morrison MA, Owen LA, Anderson K, Kinard K, Greenlees R, Novacic D, Nida Sen H, Zein WM, Rodgers GM, Vitale AT, Haider NB, Hillmer AM, Ng PC, Shankaracharya, Cheng A, Zheng L, Gillies MC, van Slegtenhorst M, van Hagen PM, Missotten TOAR, Farley GL, Polo M, Malatack J, Curtin J, Martin F, Arbuckle S, Alexander SI, Chircop M, Davila S, Digre KB, Jamieson RV, DeAngelis MM (2019). ALPK1 missense pathogenic variant in five families leads to ROSAH syndrome, an ocular multisystem autosomal dominant disorder. Genet Med, 21(9), 2103-2115. (Read full article)
    10. Aapro M, Gascn P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J (2019). Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol, 9, 1498. (Read full article)
    11. Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW (2015). A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). J Thromb Haemost, 13(8), 1405-13. (Read full article)
    12. Lee M, Keener J, Xiao J, Long Zheng X, Rodgers GM (2015). ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci, 72(2), 349-56. (Read full article)
    13. Gilreath JA, Stenehjem DD, Rodgers GM (2014). Diagnosis and treatment of cancer-related anemia. Am J Hematol, 89(2), 203-12. (Read full article)
    14. Heikal NM, Murphy KK, Crist RA, Wilson AR, Rodgers GM, Smock KJ (2013). Elevated factor IX activity is associated with an increased odds ratio for both arterial and venous thrombotic events. Am J Clin Pathol, 140(5), 680-5. (Read full article)
    15. Shirts BH, Rodgers GM, Smock KJ (2012). Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thromb Res, 130(3), e134-8. (Read full article)
    16. Lee M, Rodansky ES, Smith JK, Rodgers GM (2012). ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. Microvasc Res, 84(2), 109-15. (Read full article)
    17. Sangle NA, Rodgers GM, Smock KJ (2011). Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol, 17(1), 6-11. (Read full article)
    18. Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM (2010). The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion, 50(8), 1654-64. (Read full article)
    19. Smock KJ, Rodgers GM (2010). Laboratory evaluation of aspirin responsiveness. Am J Hematol, 85(5), 358-60. (Read full article)
    20. Smock KJ, Crist RA, Hansen SJ, Rodgers GM, Lehman CM (2010). Discard tubes are not necessary when drawing samples for specialized coagulation testing. Blood Coagul Fibrinolysis, 21(3), 279-82. (Read full article)
    21. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2009). Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res, 125(3), 220-3. (Read full article)
    22. Smock KJ, Rodgers GM (2009). Laboratory identification of lupus anticoagulants. Am J Hematol, 84(7), 440-2. (Read full article)
    23. Crist RA, Gibbs K, Rodgers GM, Smock KJ (2009). Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples. Lab Hematol, 15(4), 45-8. (Read full article)
    24. Martin C, Varner MW, Branch DW, Rodgers G, Mitchell MD (1996). Dose-related effects of low dose aspirin on hemostasis parameters and prostacyclin/thromboxane ratios in late pregnancy. Prostaglandins, 51(5), 321-30. (Read full article)
    25. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK (1992). [Pre-eclampsia: a disorders of the endothelial cells?]. Gynakologe, 25(1), 2-6. (Read full article)
    26. Rodgers GM, Barrera E Jr, Martin RR (1980). Bacillus cereus bacteremia and hemolytic anemia in a patient with hemoglobin SC disease. Arch Intern Med, 140(8), 1103-4. (Read full article)
    27. George WJ, Rodgers GM, White LA (1978). Cyclic nucleotides as regulators of erythrocyte proliferation. Adv Cyclic Nucleotide Res, 9, 517-32. (Read full article)

    Review

    1. Rodgers GM (2024). Update on iron supplementation in patients with cancer-related anemia. [Review]. Expert Rev Hematol, 17(8), 505-514. (Read full article)

    Book

    1. Bennett ST, Lehman CM, Rodgers GM (2014). Laboratory Hemostasis: A Practical Guide For Pathologists (2nd Edition). New York: Springer.

    Edited Book

    1. Greer JP, Arber DA, Glader BE, List A, Means RT, Paraskevas F, Rodgers GM (Eds.) (2014). Wintrobe's Clinical Hematology - 13th Edition. (13th ed.). Philadelphia: Lippincott Williams & Wilkins.

    Book Chapter

    1. Shami PJ, Rodgers GM (2014). Chapter 19, Endothelium: angiogenesis and the regulation of hemostasis. In Wintrobe's Clinical Hematology (13th, pp. 498–507). Philadelphia: Lippincott Williams and Wilkins.
    2. Rodgers GM, Lehman CM (2014). Chapter 45, Diagnostic approach to the bleeding disorders. In Wintrobe's Clinical Hematology (13th, pp. 1043-1057). Philadelphia: Lippincott Williams & Wilkins.
    3. Rodgers GM (2014). Chapter 46, Thrombocytopenia: pathophysiology and classification. In Wintrobe's Clinical Hematology (13th, pp. 1058-1060). Philadelphia: Lippincott Williams & Wilkins.
    4. Agarwal AM, Rodgers GM (2014). Chapter 49, Miscellaneous causes of thrombocytopenia. In Wintrobe's Clinical Hematology (13th, pp. 1097-1105). Philadelphia: Lippincott Williams & Wilkins.
    5. Rodgers GM, Rees MM (2014). Chapter 50, Bleeding disorders caused by vascular abnormalities. In Wintrobe's Clinical Hematology (13th, pp. 1106-1121). Philadelphia: Lippincott Williams & Wilkins.
    6. Powell JS, Rodgers GM (2014). Chapter 53, Inherited coagulation disorders. In Wintrobe's Clinical Hematology (13th, pp. 1143-1185). Philadelphia: Lippincott Williams & Wilkins.
    7. Rodgers GM (2014). Chapter 54, Acquired coagulation disorders. In Wintrobe's Clinical Hematology (13th, pp. 1186-1217). Philadelphia: Lippincott Williams & Wilkins.
    8. Pendleton RC, Rodgers GM (2014). Chapter 55, Thrombosis and antithrombotic therapy. In Wintrobe's Clinical Hematology (13th, pp. 1218-1257). Philadelphia: Lippincott Williams & Wilkins.
    9. Rodgers GM, Means RT (2014). Chapter 51, Thrombocytosis and essential thrombocythemia. In Wintrobe's Clinical Hematology (13th, pp. 1122-1127). Philadelphia: Lippincott, Williams & Wilkins.

    Editorial

    1. Gilreath JA, Rodgers GM (2014). Current quandaries in cancer-associated anemia. J Natl Compr Canc Netw, 12(8), 1071-5. (Read full article)
    2. Crawford J, Rodgers GM (2014). Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how? J Natl Compr Canc Netw, 12(5 Suppl), 821-4. (Read full article)

    Letter

    1. Auerbach M, Adamson J, Bircher A, Breymann C, Fishbane S, Gafter-Gvili A, Gasche C, Gilreath J, Grazzini G, Henry D, Liumbruno G, Locatelli F, Macdougall I, Munoz M, Rampton D, Rodgers G, Shander A (2015). On the safety of intravenous iron, evidence trumps conjecture. [Letter to the editor]. Haematologica, 100(5), e214-5. (Read full article)
    2. Patel SB, Rodgers GM (2014). Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. [Letter to the editor]. Haemophilia, 20(6), e411-4. (Read full article)
    3. Win K, Rodgers GM (2014). New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. [Letter to the editor]. Am J Hematol, 89(10), 1017. (Read full article)
    4. Rodgers GM (2014). Developmental hemostasis: age-specific differences in the levels of hemostatic proteins: a rebuttal. [Letter to the editor]. J Thromb Haemost, 12(2), 285. (Read full article)
    5. Rodgers, George M (2014). Age-Specific differences in the Levels of Hemostatic Proteins: A Rebuttal [Letter to the editor]. Thromb Haemost, 12, 258.

    Abstract

    1. Desai DS, Lyon E, Rodgers GM, Jama AJ, Wallentine SL, Smock KJ (2013). Gene sequencing aids in differentiation of von Willebrand disease type 2B from platelet-type vWD [Abstract]. FASEB J, 27(871), 3.
    2. Lee M, Hoyt C, Rodgers GM (2013). ADAMTS13 expressed in glioblastoma and astrocytoma cells can modulate endothelial cell migration [Abstract]. Blood, 122(21), #2306.